<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03105349</url>
  </required_header>
  <id_info>
    <org_study_id>GESIDA 9516</org_study_id>
    <nct_id>NCT03105349</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A</brief_title>
  <acronym>C-RESCUE</acronym>
  <official_title>A Phase III, Open Label, Multicentric Clinical Trial of a Single Arm of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotype 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion SEIMC-GESIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion SEIMC-GESIDA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 4 clinical trial to treat patients who have failed to treat with regimen
      based on an inhibitor of the NS5A
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the treatment will be 16 weeks and then will be a security perid with 2
      visits (Week 12 post treatment and week 24 post treatment) The study in an open label study
      with a single arm .
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No availability of investigational medication.
  </why_stopped>
  <start_date type="Anticipated">July 1, 2017</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of patients achieved SVR12</measure>
    <time_frame>Week 12 post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects infected with HCV genotype 1a with reference VARs NS5A / NS3 who achieved RVS12.</measure>
    <time_frame>Week 12 post treatment</time_frame>
    <description>To analyze the impact of VARs NS5A/NS3 on RVS12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects infected with HCV genotype 1b with reference VARs NS5A / NS3 who achieved RVS12.</measure>
    <time_frame>Week 12 post treatment</time_frame>
    <description>Analyze the impact of VARs NS5A/NS3 on RVS12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects infected with HCV genotype 4 with reference VARs NS5A /NS3 who achieved RVS12.</measure>
    <time_frame>Week 12 post treatment</time_frame>
    <description>Analyze the impact of VARs NS5A/NS3 on RVS12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects infected with HCV genotypes 1.4 with reference VARs NS5A /NS3 who achieved RVS24.</measure>
    <time_frame>Week 24 post treatment</time_frame>
    <description>Analyze the impact of VARs NS5A/NS3 on RVS24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occurrence of Viral resistance variants (VARs) to NS5A or elbasvir, to NS3 or grazoprevir and to NS5B or SOF in patients who did not reach SVR12 after 16 weeks of re-treatment</measure>
    <time_frame>Week 16</time_frame>
    <description>the occurrence of resistance in patients who did not reach SVR12 after 16 weeks of re-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occurrence of resistance variants (VARs) viral to NS5A or elbasvir, to NS3 or grazoprevir, and to NS5B or SOF in HIV patients included</measure>
    <time_frame>Week 12 post treatment</time_frame>
    <description>The impact of VARs NS5A/NS3 on RVS12
The proportion of subjects developing HIV-1 virological failure (HIV RNA&gt; 200 Copies / mL), confirmed in 2 consecutive tests with at least 2 weeks between them.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects developing HIV-1 virological failure (HIV RNA&gt; 200 Copies / mL), confirmed in 2 consecutive tests with at least 2 weeks between them</measure>
    <time_frame>Week 4, week 8, week 12 and week 16</time_frame>
    <description>the impact of treatment with EL / BRA plus SOFT and ribavirin in HIV-1 subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects experiencing adverse events of high laboratory values who report as ECI at any time during the study period.</measure>
    <time_frame>Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with at least one adverse experience</measure>
    <time_frame>Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with an adverse experience related to medication</measure>
    <time_frame>Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with a severe adverse experience</measure>
    <time_frame>Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with a serious adverse experience related to medication</measure>
    <time_frame>Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with an adverse experience leading to disruption</measure>
    <time_frame>Week 4, week 8, week 12, week 16, week 12 post-treatment and week 24 post-treatment</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HCV</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 weeks treatment with elbasvir/grazoprevir plus sofosbuvir and ribavirina</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elbasvir/grazoprevir</intervention_name>
    <description>16 weeks treatment</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>Zepatier</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>16 weeks treatment</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>16 weeks treatment</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with chronic HCV genotype 1, 4 infection with or without HIV infection aged 18
             years or above

          -  HCV RNA plasma concentration of at least 1000 IU / mL

          -  Subjects previously treated with NS5A-based regimens for at least 8 weeks.

          -  Patients with HCV relapse after receiving a complete treatment with NS5A-based AAD
             regimen for at least 8 weeks and becoming undetectable at the end of treatment.
             Relapse is defined as a confirmed HCV RNA detectable upon completion of therapy of A5
             based on NS5A against HCV.

          -  Subjects with compensated hepatic cirrhosis (Child A) could be included.

          -  For patients with HIV coinfection:

               -  Be infected with HIV-1, documented by any rapid HIV test with the corresponding
                  license and confirmed by a Western blot or second antibody test using a method
                  other than the initial rapid HIV and / or I / CIA method or by HIV-1 p24 antigen
                  or viral load of HIV-1 RNA plasma.

               -  Be on stable HIV antiretroviral therapy (ART) for at least 4 weeks prior to entry
                  into the study using a dual ITN backbone of tenofovir or abacavir and
                  emtricitabine or lamivudine PLUS raltegravir or dolutegravir or rilpivirine (with
                  CD4 + T cell count&gt; 100 cells / mm 3 and undetectable HIV-1 RNA at baseline.
                  Results from prior analysis will be accepted within 24 weeks prior to study
                  entry).

        Exclusion Criteria:

          -  Subjects with hepatitis other than C or steatosis.

          -  Subjects previously treated less than 8 weeks with regimens based on NS5A.

          -  Evidence of previous hepatocellular carcinoma although it has criteria of cure

          -  Subjects with past or current decompensated liver disease; Only decompensated patients
             who have received a liver transplant and have not decompensated after transplantation
             will be included.

          -  Subjects suspected of clinical or genotypic reinfection of HCV.

          -  Subject with HCV response regrowth while receiving NS5A-based ADA therapy against HCV.
             Said regrowth is defined as a confirmation of detectable HCV RNA after achieving
             undetectable HCV RNA during NS5A-based AADs against HCV.

          -  Recent history of drug or alcohol abuse.

          -  Important comorbidities.

               -  Pregnant, lactating or non-lactating women Contraceptives, if they are women of
                  childbearing age. Women of childbearing age are defined as those women who have
                  not undergone permanent infertility procedures or who have been amenorrheic for
                  less than 12 months.

               -  Subjects with a glomerular filtration rate of less than 30 ml / min.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Univ. La Paz</name>
      <address>
        <city>Madrid</city>
        <state>Madri</state>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Gregorio Mara√±on</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospita 12 de octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

